The aim of the current study was to investigate the effectiveness and clinicalfeasibilityofBiyeom-goforthetreatmentofnasalsymptomsassociatedwith rhinitis. Design: Prospectiveobservationalstudy. Setting: ThisstudywasconductedattheWoosukKoreanMedicineMedicalCenter inSouthKorea. Participants: Fifty-eightpatientswithrhinitisparticipatedinthisstudy.Allpatients receivedBiyeom-gotreatment>3timesdailyforatotalof4weeks. Main outcome measures: Theprimaryoutcomewasthetotalnasalsymptomscore. Mini-rhinoconjunctivitis quality of life questionnaire, nasal endoscopy index, total serumimmunoglobulinElevelsandimmunologicfactorsinnasallavagefluidwere alsomeasured. Results: Biyeom-goadministrationwasassociatedwithsignificantimprovementsin totalnasalsymptomsscores(P<.0001)andmini-rhinoconjunctivitisqualityoflife questionnairescores(P<.0001)inatime-dependentmanner.Thenasalendoscopy indexalsosignificantlyimprovedatweeks2(P=.0049),3(P<.0001)and4(P=.0001) afterBiyeom-gotreatment.Significantly,increasedinterleukin-2levels(P=.005)and decreased interleukin-8, chemokine (C-C motif) ligand (CCL) 5, chemokine (C-X-C motif)ligand(CXCL)9,CCL2andCXCL10levelswereobservedinthenasallavage fluid. Conclusions: ThepresentfindingssuggestthatBiyeom-gomaybebeneficialforthe managementofrhinitissymptomsandrhinitis-associatedqualityoflife.Furtherwelldesigned randomised controlled trials are needed to evaluate the effectiveness of Biyeom-goforrhinitis. ThisisanopenaccessarticleunderthetermsoftheCreativeCommonsAttribution-NonCommercial-NoDerivsLicense,whichpermitsuseanddistributionin anymedium,providedtheoriginalworkisproperlycited,theuseisnon-commercialandnomodificationsoradaptationsaremade. 